Pfizer公司的背景是什麼？

詳細公司背景可參考: [https://www.pfizer.com](https://www.pfizer.com)。

Pfizer

PFE

50.100

▲1.800

▲3.73%

概況消息

最少15分鐘延遲，股票資訊由第三方資訊供應商提供

・Pfizer - 延遲價格・最後更新於 12/08 12:00

最高位: 50.385
最低位: 48.550
開市價: --
前收市價: 48.300
成交量(千): 1,587.59
成交額(百萬): 578.41
買入: --
賣出: --
每手股數: --
市值(百萬): 281,178.83
市盈率: 9.750
息率: 3.29%
差價: --
52週高低: 61.710 - 40.940

所有資料不保證絕對正確、完整、或實時，僅作為參考使用。投資涉及風險，過往業績並不代表將來表現，作任何投資決定或交易前，閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

企業資料

公司名稱: Pfizer
證券代碼: PFE.US
所屬板塊: Drug Manufacturers - General
公司業務: Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
發行量: 5612866598
公司總部: 235 East 42nd Street
公司網址: https://www.pfizer.com
公司電話: +1 212 733-2323

關於

Pfizer(PFE.US)所屬的行業板塊為Drug Manufacturers - General。

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.

截至12/08 12:00:00，Pfizer的股價升3.73，市值281,178.83百萬。Pfizer的市盈率及息率分別為9.750及3.29%。

詳細公司背景可參考: https://www.pfizer.com。

快訊

資訊

虛擬市場

Pfizer

企業資料

最新發佈

美股異動 | 輝瑞漲2% 奧密克戎開發新冠疫苗有望被歐盟批准

美股異動 | 輝瑞漲2% 奧密克戎開發新冠疫苗有望被歐盟批准

格隆匯快訊

美股抗疫概念股走弱

美股抗疫概念股走弱

關於